Skip to main content

Advertisement

SpringerLink
Log in

Safe Travel Preparation for HIV-Infected Patients

  • HIV/AIDs (C Yoon, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Infectious diseases are a risk when traveling internationally, and it is important to know the potential disease burden of a region and take appropriate preventative actions before traveling. For individuals with HIV, there are special considerations and contradictions for various vaccines and medications as well as interactions with likely antiviral drugs. The purpose of this review is to summarize the vaccine and medication recommendations for travelers with HIV infection. We also review recent studies to update these recommendations.

Recent Findings

The recommendation for yellow fever vaccine has changed in June of 2016, and it is now a once in a lifetime vaccine instead of being given every 10 years. A new cholera vaccine, Vaxchora™ was approved in 2016. Since it is a live vaccine, its impact on immunocompromised individuals is still not fully known. A recent study found that immunocompromised patients responded well to the hepatitis A vaccine, although acquiring immunity may take longer than in non-immunocompromised people. There are some new anti-viral medicines that need to be considered with interactions for other travel medicines, in particular, the anti-malaria drugs.

Summary

This review provides current knowledge on how HIV-infected and immunocompromised persons respond to medications and vaccines for prevention of infectious diseases in travelers. These recommendations will be useful to recommend safer travel for the HIV-infected patient. Some newer vaccines and medications will need further evaluation and assessment to determine safety and impact on HIV-positive travelers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• Centers for Disease Control and Prevention. CDC Yellow Book 2018: Health Information for International Travel. New York: Oxford University Press; 2017. p. 153–154, 233–235, 342–343, 352–354, 557–571. The 2018 CDC Yellow Book is the most up-to-date guide for international travel disease risk by the Centers for Disease Control, and includes information on immunocompromised individuals and vaccination recommendations, and thus is of greatest importance for this review.

  2. • Vaccine Recommendations and Guidelines of the ACIP. In: Centers for Disease Control and Prevention, 2018. https://www.cdc.gov/vaccines/hcp/acip-recs/index.html. Accessed 17 Sep 2018. This source from the Centers for Disease Control provides information on their current vaccination recommendations.

  3. Yellow fever global annual reported cases and YFV coverage, 1980-2016 In: Yellow fever: maps and graphics. World Health Organization, 2017. http://www.who.int/emergencies/yellow-fever/maps/en/.

  4. Hamer DH, Angelo K, Caumes E, van Genderen PJ, Florescu SA, Popescu CP, et al. Fatal yellow fever in travelers to Brazil, 2018. Morb Mortal Wkly Rep. 2018;67(11):340–1.

    Article  Google Scholar 

  5. Barte, H., Horvath, T.H. and Rutherford, G.W., 2014. Yellow fever vaccine for patients with HIV infection. Cochrane Database Syst Rev, (1), pp.CD010929. https://doi.org/10.1002/14651858.CD010929.pub2.

  6. • Wieten RW, Goorhuis A, Jonker EFF, de Bree GJ, de Visser AW, van Genderen PJJ, et al. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immunocompromised patients. J Infect. 2016;72(6):713–22. This is a recent study looking at the effects of the yellow fever vaccination in immunocompromised persons.

    Article  CAS  Google Scholar 

  7. • New yellow fever vaccination requirements for travellers. In: World Health Organization. WHO. 2016. http://www.who.int/ith/updates/20160727/en/. This is an updated recommendation by the World Health Organization on yellow fever vaccination for international travel.

  8. Staples JE, Bocchini JJ, Rubin L, Fischer M. Yellow fever vaccine booster doses: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb. Mortal. Wkly Rep. 2015;64(23):647–50.

    PubMed  PubMed Central  Google Scholar 

  9. Vaccination. In: Typhoid fever and paratyphoid fever. Centers for Disease Control and Prevention. 2018. https://www.cdc.gov/typhoid-fever/typhoid-vaccination.html. Accessed Sep 2018

  10. Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, Bennish ML. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med. 2006;354(23):2452–62.

    Article  CAS  Google Scholar 

  11. • Grading of recommendations, assessment, development, and evaluation (GRADE) for Lyophilized CVD 103-HgR Vaccine. In: Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. 2017. https://www.cdc.gov/vaccines/acip/recs/grade/cholera-CVD-103-HgR.html. This important source provides information on the newly developed cholera vaccination.

  12. Perry RT, Plowe CV, Koumare B, Bougoudogo F, Kotloff KL, Losonsky GA, et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull World Health Organ. 1998;76(1):63–71.

  13. Garcia Garrido HM, Wieten RW, Grobusch MP, Goorhuis A. Response to hepatitis A vaccination in immunocompromised travelers. J Infect Dis. 2015;212(3):378–85.

    Article  Google Scholar 

  14. Choosing a Drug to Prevent Malaria. In: Malaria. Centers for Disease Control and Prevention. 2018. https://www.cdc.gov/malaria/travelers/drugs.html. Accesed Sep 2018

Download references

Author information

Authors and Affiliations

  1. Stanford University, 531 Lasuen Mall, PO Box 16701, Stanford, CA, 94309, USA

    David Mariano

  2. Infectious Disease & Geographic Medicine, Redwood City Kaiser, The Kaiser Permanente Medical Group, Travel Medicine Services, 1192 Veterans Blvd, Redwood City, CA, 94063, USA

    Darvin Scott Smith

Authors
  1. David Mariano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Darvin Scott Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Darvin Scott Smith.

Ethics declarations

Conflict of Interest

David Mariano and Darvin Scott Smith declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on HIV/AIDs

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mariano, D., Smith, D.S. Safe Travel Preparation for HIV-Infected Patients. Curr Infect Dis Rep 21, 15 (2019). https://doi.org/10.1007/s11908-019-0667-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11908-019-0667-8

Keywords

Search

Navigation